Oncolytic Virus as a New Treatment Technology in Cancer
Journal of Biochemical and Molecular Toxicology · 2025-06 · 39 (6)
DOI: 10.1002/jbt.70352 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 16.06.2025. Verfasst von Mohammed Asiri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Neoplasms, Oncolytic Viruses, Oncolytic Virotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 151 Literaturangaben. Gefördert von: This research was supported by the King Khalid University., King Khalid University.
Abstract (Originalsprache)
Oncolytic viruses (OVs) are promising antineoplastic agents, leveraging unique capacities of certain viruses to specifically damage malignant cells without affecting normal tissues. Current article explores the mechanisms by which OVs exploit the dysregulated biology of cancer cells, leading to tumor regression and enhanced immune responses. Recent advancements in genetic engineering have led to developing modified viruses that can deliver therapeutic genes or immune‐stimulatory proteins, further amplifying their antitumor effects. Clinical trials have demonstrated manageable safety profiles, with OVs therapies showing potential for durable responses through the induction of immunogenic cell death and long‐term immune memory. However, challenges such as the hostile tumor microenvironment and the need for predictive biomarkers remain critical barriers to widespread clinical application. This article discusses ongoing research aimed at overcoming these challenges, including combination therapies with checkpoint inhibitors and strategies to enhance viral delivery. Integrating OV into existing treatment paradigms can significantly improve patient outcomes across diverse malignancies. This review highlights the transformative capacity of OV therapy as a cornerstone of future treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
- Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Anbar, Iraq.
- Department of biochemistry, College of medicine, Imam Mohammad Ibn Saud University (IMSIU), Saudi Arabia.
- Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Marwadi University Research Center, Department of Microbiology, Faculty of Science, Marwadi University, Rajkot, India.
- Department of Surgery, National Institute of Medical Sciences, NIMS University Rajasthan, Jaipur, India.
ORCID-Profile: Hussein Riyadh Abdul Kareem Al-Hetty, Reham Abdullah Al-Dhelaan, Soha Said Zakaria Shehata
Förderung
- This research was supported by the King Khalid University.
- King Khalid University
Zitieren
APA
Asiri, M., Abdul Kareem Al-Hetty, H. R., Al-Dhelaan, R. A., Shehata, S. S. Z., Bishoyi, A. K., Vashishth, R., Uthirapathy, S., Satyam Naidu, K., Arya, R., & Ali-Hussein, Z. (2025). Oncolytic Virus as a New Treatment Technology in Cancer. Journal of Biochemical and Molecular Toxicology, 39(6). https://doi.org/10.1002/jbt.70352
Vancouver
Asiri M, Abdul Kareem Al-Hetty HR, Al-Dhelaan RA, Shehata SSZ, Bishoyi AK, Vashishth R, et al. Oncolytic Virus as a New Treatment Technology in Cancer. Journal of Biochemical and Molecular Toxicology. 2025;39(6). doi:10.1002/jbt.70352
BibTeX
@article{Asiri2025,
author = {Asiri, Mohammed and Abdul Kareem Al-Hetty, Hussein Riyadh and Al-Dhelaan, Reham Abdullah and Shehata, Soha Said Zakaria and Bishoyi, Ashok Kumar and Vashishth, Raghav and Uthirapathy, Subasini and Satyam Naidu, Kandi and Arya, Renu and Ali-Hussein, Zainab},
title = {Oncolytic Virus as a New Treatment Technology in Cancer},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
volume = {39},
number = {6},
doi = {10.1002/jbt.70352}
}
EUVIMED